An Observational Clinical Study on the Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Latest Information Update: 09 Aug 2022
Price :
$35 *
At a glance
- Drugs Anti-CD19/CD22 CAR NK cell therapy Allife Medical Science and Technology (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 08 Feb 2019 New trial record